Tab Application Banner
  • Users Online: 812
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 14  |  Issue : 1  |  Page : 17-20

Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study group experience


1 Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, Bengaluru, Karnataka, India
2 Department of Rheumatology, Manipal Hospital, Bengaluru, Karnataka, India
3 Department of Rheumatology, Fortis Hospital, Bengaluru, Karnataka, India
4 Chanre Rheumatology and Immunology Research Centre, Bengaluru, Karnataka, India
5 Department of Rheumatology, Sakra Hospital, Bengaluru, Karnataka, India
6 Department of Rheumatology, Columbia Asia Hospital, Bengaluru, Karnataka, India
7 Department of Rheumatology, Apollo Hospital, Bengaluru, Karnataka, India
8 Samarpan Health Centre, Bengaluru, Karnataka, India
9 Department of Rheumatology, Vikram Hospital and Heart Care, Mysore, Karnataka, India
10 Department of Rheumatology, Narayana Hrudalaya, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Vineeta Shobha
St. John's Medical College and Hospital, Sarjapur Road, Bengaluru - 560 034, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_79_18

Rights and Permissions

Introduction: Biologics are widely used in Autoimmune rheumatologic diseases (AIRDs), however the need to capture real life data which monitors indications, adverse reactions cannot be over emphasized. Methods: This is a cross-sectional ambidirectional multi-center study conducted over 8 months from January 2016 to August 2016, across 12 tertiary care rheumatology centers in Karnataka, India conducted by members of the Karnataka Rheumatology Association. Results: The most common biologic prescribed is tumour necrosis factor antagonist etanercept. Commonest indication for biologics being Spondyloarthropathy group of disorders. The most common cause for stopping biologics is clinical improvement. Only 4.8% of patents discontinued biologics due to ADRs. Conclusion: The prescribing patterns, mode of use, prebiologics screening methods, and adverse event profile are similar across centres. Pre-screening for latent tuberculosis (TB) is consistent across centres, and TB prophylaxis appears to be effective in preventing its reactivation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed841    
    Printed32    
    Emailed0    
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal